Ad
related to: competition in the pharmaceutical industry
Search results
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Zacks via Yahoo Finance· 4 days agoRoche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced...
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on May 30
Digital Journal· 4 days ago...other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk,...
Zacks· 2 days agoMay 23, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial ...
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S....
WTRF Wheeling· 4 days agoBiocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration ...
Sanofi partners with OpenAI: here's how it will mitigate AI risks | Invezz
Invezz· 4 days agoWorking with the AI company will help Sanofi “go to market faster with our drugs” and address the...
Earnings call: 111 Inc. outlines operational profitability in Q1 2024 By Investing.com
Investing.com· 1 day ago111 Inc. (NASDAQ: YI), a Chinese healthcare e-commerce operator, has announced its first operational...
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post...
Morningstar· 4 days agoToday AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing ...
Why Jamie Dimon’s Buyback Bombshell Is a Warning for Stocks, and 5 Other Things to Know Before the...
Barrons.com· 4 days agoNorwegian Cruise Line soars on profit guidance, Red Lobster bankruptcy blamed on shrimp promotion,...
US Patent Office ARP Affirms the Use of Means-Plus-Function Limitations to Claim Antibodies | JD...
JD Supra· 1 day agoIn the recent decision Ex parte Chamberlain, Appeal 22-1944 (Xencor), the United States Patent and Trademark Office’s new Appeals Review Panel provided clarity regarding its stance on means-plus-function ...
Record results for Turpaz Industries group in revenues, gross profit and EBITDA in the first quarter...
FOX 23 News Albany· 5 days agoThe group's sales grew by 26.2% and amounted to a record 39 million dollars with an adjusted EBITDA rate of 21.5%, which is one of the highest in the industry in which the ...
